Sponsors’ Use Of Adaptive Designs Appears To Be Growing
This article was originally published in Pharmaceutical Approvals Monthly
A Drug Information Association working group survey found 477 studies between Jan. 1, 2008 and Sept. 1, 2011 utilized some type of adaptive design.
You may also be interested in...
Roche is innovating in the structure of clinical development to manage the increasingly complex knowledge of cancer biology, using adaptive trial designs and extensive analysis of responders to find biomarkers that can inform, adjust and enrich clinical studies in a continually iterative process of “learning on the go.”
Large study tracking drug indications pursued by more than 800 companies over almost a decade finds that only one in 10 wound up getting approved. By therapeutic area, Phase III success rates were lowest in cancer and cardiovascular medicine, and highest in diabetes, infectious and autoimmune disease.
Adaptive designs and studies at multiple infection sites are among industry suggestions to the agency as possible new approaches to developing drugs to fight bacterial infections.